Functional MRI of Stress in Obesity
Functional Magnetic Resonance Imaging of Stress in Obesity
1 other identifier
observational
50
1 country
1
Brief Summary
To examine the influence of obesity on brain activation during food cue, stress, and neutral relaxing conditions
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2008
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2008
CompletedFirst Submitted
Initial submission to the registry
October 29, 2012
CompletedFirst Posted
Study publicly available on registry
November 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedJuly 13, 2022
July 1, 2022
5.8 years
October 29, 2012
July 11, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
No outcome measures for this study, this is an imaging study only
Upon study completion
Study Arms (2)
Healthy
Subjects deemed to be medically healthy
Obese
Subjects deemed to be medically obese
Eligibility Criteria
30 obese subjects and 30 matched healthy controls will be recruited for this study.
You may qualify if:
- Between ages 18-50 years old.
- Able to read and write.
- negative urine toxicology screens during intake appointments indicating no history of current or past dependence on alcohol or illicit drug use.
- WOMEN: have a regular menstrual cycle.
- BMI: 30 \< BMI \< 35 for obese subjects (upper limit of 35 selected given our experience with heavier individuals fitting comfortably in the fMRI scanner) and 18.5 \< BMI \<25 for normal weight subjects (Institute, 2006)
You may not qualify if:
- any major neurological illness or injury and any current or prior clinically significant mental health (including PTSD) or substance use disorder (with exception of nicotine dependence) as determined by SCID interview;
- Regular use of any psychoactive drugs including anxiolytics and antidepressants.
- Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, liver, thyroid pathology; subjects on medications for any medical condition will be excluded.
- Any subjects with foreign ferromagnetic metal objects in their body or other MR contraindications will be excluded including subjects who work as welders.
- Women on oral contraceptives, peri- and post-menopausal women, and pregnant or lactating women (as alterations in stress response are associated with these states).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Yale Universitylead
Study Sites (1)
Yale University School of Medicine
New Haven, Connecticut, 06519, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Marc N Potenza, MD, PhD
Yale University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 29, 2012
First Posted
November 1, 2012
Study Start
May 1, 2008
Primary Completion
March 1, 2014
Study Completion
March 1, 2014
Last Updated
July 13, 2022
Record last verified: 2022-07